Introduction {#sec0005}
============

Tuberculosis remains a common disease in both developing and developed countries. Although the global incidence of tuberculosis has been on the decline, the worldwide disease burden remains a major health problem. One-third of the world's population is estimated to be infected with *Mycobacterium tuberculosis*, and 10% of these individuals develop active tuberculosis during their lifetime \[[@bib0005]\]. While treatment with appropriate antitubercular drugs is important, they have some characteristic complications. A paradoxical reaction (PR) is defined as transient worsening of pre-existing symptoms or appearance of new signs, symptoms, or radiographic manifestations of tuberculosis that occur after treatment initiation \[[@bib0010]\]. A PR can be diagnosed only after ruling out treatment failure, poor compliance, drug resistance, side effects of antitubercular therapy (ATT), or another infection. This phenomenon often occurs in individuals infected with human immunodeficiency virus (HIV), but it is not common in individuals who are HIV-negative \[[@bib0015]\]. A PR has been reported to occur in 2.4% of cases with pulmonary tuberculosis \[[@bib0020]\]. However, it is rare in miliary tuberculosis and has only been reported sporadically in case reports. Here we report a case of miliary tuberculosis in a HIV- negative patient who developed a PR during appropriate ATT and also discuss similar cases reported in the literature.

Case report {#sec0010}
===========

A 78-year-old woman presented to our hospital complaining of general malaise, loss of appetite for 2 weeks, and fever for 10 days. She had been diagnosed with pulmonary tuberculosis when she was in elementary school and had been treated with ATT, although the specific details of the therapy were unknown. She was admitted to our hospital for further investigation.

Physical examination revealed a heart rate of 78 beats/min; blood pressure of 153/80 mmHg; body temperature of 38.4 °C; and SpO~2~ of 97% (on room air). Chest auscultation revealed no rhonchi, crackles, or wheezes. A chest radiograph showed diffuse reticular nodule ([Fig. 1](#fig0005){ref-type="fig"}), and computed tomography (CT) showed diffuse, bilateral, discrete miliary nodules ([Fig. 2](#fig0010){ref-type="fig"}a). Laboratory findings revealed a hemoglobin level of 10.0 g/dl, white blood cell count of 4300 cells/mm^3^ with 67.6% neutrophils, and C-reactive protein level of 6.6 mg/dl.Fig. 1Chest X-ray on admission showing diffuse reticular nodule.Fig. 1Fig. 2(a) Chest CT on admission showing diffuse, bilateral, discrete miliary nodules. (b) On day 9 of ATT, chest CT showing a new localized GGO in the right upper lobe. (c) On day 18, chest CT showing improvement of the GGO. (d) On day 28, chest CT showing no recurrence of the GGO after discontinuation of steroid therapy. Abbreviations: CT, computed tomography; ATT, antitubercular therapy; GGO, ground-glass opacity.Fig. 2

Bronchoscopy was performed on the 2nd day after admission and revealed no specific abnormalities of the bronchial walls. Bronchial washings of the right upper lobe and transbronchial lung biopsies in subsegments B2b, B3a and B9 were performed. Sputum, blood, urine, bronchial lavage fluid, and lung tissue smears were negative for acid-fast bacilli. Polymerase chain reaction for *M. tuberculosis* DNA isolated from the bronchial lavage fluid was also negative.

Despite negative test results for acid-fast bacilli, the patient was diagnosed with miliary tuberculosis on the basis of clinical history and radiological findings. She was subsequently started on a four-drug ATT comprising isoniazid (200 mg/day), rifampicin (300 mg/day), ethambutol (500 mg/day), and pyrazinamide (1000 mg/day), which temporarily improved her fever ([Fig. 3](#fig0015){ref-type="fig"}). However, 9 days after starting ATT, she developed a spiking fever and worsening malaise. Repeat CT showed new localized ground-glass opacity (GGO) in the right upper lobe ([Fig. 2](#fig0010){ref-type="fig"}b).Fig. 3**Hospital course depicting the patient's fever and antitubercular therapy regimen**. On day 33, because of a drug fever with eosinophilia and elevated liver enzyme levels (AST 176 U/l, ALT 120 U/l), antitubercular therapy was withdrawn for 1 week. Arrows and letters indicate when chest CT described in [Fig. 2](#fig0010){ref-type="fig"} was performed. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.Fig. 3

Sputum Gram staining and sputum and blood cultures were negative for secondary bacterial infection. Additional laboratory investigations revealed the following results: Krebs von den Lungen-6 level, 306 U/ml (normal level; \<500 U/ml); surfactant protein-D level, 69.5 ng/ml (normal level; \<110 ng/ml); procalcitonin level, 0.1 ng/ml; HIV-1 and -2 antibody, negative; and cytomegalovirus antigen, negative. Krebs von den Lungen-6 and surfactant protein-D are serum markers indicating the disease activity of interstitial pneumonia. Considering the clinical course and radiological worsening after initiation of ATT, she was considered to have a PR as a result of the therapy.

Because of her increased general fatigue, repeat bronchoscopy was waived, and she was managed with oral prednisolone at a dose of 25 mg/day while continuing ATT. Her fever and malaise gradually resolved. Eight days after the initiation of steroid therapy (18 days after the initiation of ATT), CT showed improvement in the GGO ([Fig. 2](#fig0010){ref-type="fig"}c). Oral prednisolone was then tapered over a period of 2 weeks. Even after discontinuation of the steroid therapy, there was no recurrence of the GGO on follow-up CT ([Fig. 2](#fig0010){ref-type="fig"}d).

She again experienced fever accompanied by eosinophilia and elevated liver enzyme levels; these findings were attributed to the drug fever. The ATT was ceased for 1 week, after which a modified regimen was administered ([Fig. 3](#fig0015){ref-type="fig"}). She was discharged on day 63, and hyposensitization therapy for rifampicin was initiated. ATT with isoniazid (300 mg/day) and rifampicin (450 mg/day) was continued. On follow-up CT, the GGO had disappeared and the miliary nodule was improving.

Discussion {#sec0015}
==========

A PR to ATT is a well-recognized phenomenon. In this case, an individual who was HIV-negative developed a localized GGO as a PR to ATT. Although her sputum smear was negative for acid-fast bacilli, the diagnosis of miliary tuberculosis was based on the clinical and radiological features as the sputum smear is reported to be positive in only one-third of patients with miliary tuberculosis \[[@bib0025]\]. The PR was successfully treated with a short course of steroids while ATT was continued, and the complication did not recur thereafter.

Our patient developed worsening clinical and radiological features on day 9 of ATT. Bacteriological and serologic testing did not indicate any secondary infection. Drug-induced pneumonia secondary to the ATT seemed unlikely because the new GGO was unilateral and limited to the right upper lobe. It also supports the idea that serum markers, Krebs von den Lungen-6 and surfactant protein-D were normal. It did not recur with continuation of ATT even though the steroid therapy was discontinued. Exacerbation of miliary tuberculosis was also unlikely because the miliary nodule was seen to be improving with ATT. Therefore, we clinically diagnosed this phenomenon as a PR even though the patient's condition did not allow bronchoscopy to be performed.

It has been postulated that the mechanism underlying a PR is local rebound immunological response. The destruction of mycobacteria and release of tubercular proteins invoke mixed type 1 and type 2 helper T-lymphocyte inflammatory responses \[[@bib0030]\]. The inflamed tissue becomes extremely sensitive to tumor necrosis factor-α, releasing cytokines that cause necrosis, first of the microvasculature and subsequently the whole tissue \[[@bib0030]\].

To our knowledge, besides our case, 28 cases of a PR in miliary tuberculosis in non-HIV-infected patients have been reported in the past 40 years ([Table 1](#tbl0005){ref-type="table"}) \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160]\]. The manifestations described depended on the site of involvement. It occurred most commonly in the central nervous system (39%), followed by skin (25%), lymph nodes (18%), bone and muscles (7%), lung (7%), and gastrointestinal tract (4%). However, there may be selection bias in the spectrum of findings in the PRs identified in these reports because unusual or severe cases are more likely to be reported. The occurrence of PR varied from a few days to a few months after initiation of ATT, although it was likely to occur earlier in patients not on immunosuppressive therapy. The outcome was generally good, although sequelae could occur with a central nervous system PR. Treatments included surgery and steroid administration. A PR in the lung is comparatively atypical and localized GGO is especially rare, although some cases of acute respiratory distress syndrome in miliary tuberculosis have been reported \[[@bib0165], [@bib0170], [@bib0175]\]. Our case illustrates that a PR in the lung may present with localized GGO. As in the other reports, our patient's PR improved following administration of steroids with continued ATT.Table 1Summary of paradoxical reactions in miliary tuberculosis among non-HIV infected patients.Table 1AuthorAge/sexImmunodeficiencyPresentation of PROnset after initiation of ATTAdditional treatmentOutcomeChambers et al. \[[@bib0035]\]34/MNoneConvulsions and increase in previously noted brain lesions7 monthsAnticonvulsantsImprovedRietbroek et al. \[[@bib0040]\]64/FPrednisone and azathioprine for scleroderma and polymyositisSubcutaneous abscesses17 daysDrainageImprovedChen et al. \[[@bib0045]\]32/FSystemic lupus erythematosusSubcutaneous abscesses1 monthNoneImprovedValdez et al. \[[@bib0050]\]28/MNoneSubcutaneous abscesses2 monthsAspirationImprovedBerg et al. \[[@bib0055]\]23/FAzathioprine and prednisone for dermatomyositisFever and abscesses of both thighs13 weeksFluid aspirationImprovedMert et al. \[[@bib0060]\]37/FPrednisolone and methotrexate for rheumatoid arthritis and dermatomyositisSubcutaneous abscesses5 monthsDrainageImprovedGarcia Vidal et al. \[[@bib0065]\]49/FInfliximab for rheumatoid arthritisFever and lymphadenopathy5 weeksSurgeryImprovedGarcia Vidal et al. \[[@bib0065]\]48/FInfliximab for rheumatoid arthritisLymphadenopathy8 weeksSurgeryImprovedToutous-Trellu et al. \[[@bib0070]\]81/FPrednisone and methotrexate for rheumatoid polyarthritisFever and skin ulcer6 weeksPrednisoneImprovedYoon et al. \[[@bib0075]\]38/MInfliximab and methylprednisolone for Crohn diseaseRight supraclavicular lymphadenopathy3 monthsSurgeryImprovedMelboucy-Belkhir et al. \[[@bib0080]\]56/FInfliximab for ankylosing spondylitisRight supraclavicular lymphadenopathy3 monthsPrednisolone and surgical excisionImprovedMatsuyama et al. \[[@bib0085]\]72/FDiabetes mellitus Prednisolone for systemic sclerosisLeft femur pain and swelling of lateral great adductor muscle abscess3 monthsPrednisolone increasedImprovedHassan et al. \[[@bib0090]\]29/FVitamin D deficiencyAbscess of left knee4 monthsOral steroidImprovedChaudhry et al. \[[@bib0095]\]31/FNoneSpastic ataxia3 weeksPrednisoloneImprovedJorge et al. \[[@bib0100]\]20/MMethotrexate and infliximab for Juvenile idiopathic arthritisSevere cerebrospinal fluid and brain inflammatory reaction in pre-existing tuberculous meningitisNACorticosteroids and infliximabImprovedMorioka et al. \[[@bib0105]\]78/FPrednisolone for tuberculous meningitisDizziness and right temporal lobe infarct40 daysExisting prednisoloneImprovedGupta et al. \[[@bib0110]\]18/MNoneFever, cough, dyspnea, and pulmonary infiltration10 daysPrednisoneImprovedDas et al. \[[@bib0115]\]22/FNoneHeadache, vomiting, photophobia, and pain and erythema of the left eye; multiple small nodular and ring-enhancing lesions with edema in both cerebral hemispheres1 monthDexamethasone and lamotrigineImprovedDas et al. \[[@bib0115]\]10/FNoneGeneralized tonic clonic seizures with right temporal conglomerated nodules and perilesional edema2 monthsOral phenytoin and prednisoloneImprovedYilmaz et al. \[[@bib0120]\]20/MNoneDiminished visual acuity in the left eye due to a pre-existing choroidal tuberculoma7 daysNonePersistent decrease in visual acuityKim et al. \[[@bib0125]\]76/FNoneRight hemiparesis and increased size of pre-existing brain lesions1 monthStopped pyrazinamide and craniotomy and mass resectionImprovedFalkenstern-Ge et al. \[[@bib0130]\]37/MAdalimumab for psoriatic arthritisFever and progressive bilateral pulmonary infiltrates6 weeksPrednisoloneImprovedXie et al. \[[@bib0135]\]55/FHigh-titer anti IFN-γ autoantibodiesLytic lesions in the left humeral head14 weeksPrednisoloneImprovedSaitou et al. \[[@bib0140]\]61/MMethotrexate, tacrolimus, and prednisolone for dermatomyositisBowel perforation97 daysSurgeryImprovedBacha et al. \[[@bib0145]\]21/MNoneLeft cervical lymphadenopathy, pulmonary, pleural, costal and spinal location tuberculosis8 monthsNoneImprovedMin et al. \[[@bib0150]\]47/MNoneSudden hearing loss, tinnitus in right ear, and multiple nodule in the brain parenchyma7 daysAdded pyrazinamide and prednisolonePersistent hearing lossWakamiya et al. \[[@bib0155]\]63/MCyclosporine and mycophenolate mofetil for heart transplantationFever and confusion Cerebral tuberculomas in the subarachnoid space1 monthDexamethasoneImprovedKim et al. \[[@bib0160]\]65/FTacrolimus, mycophenolate mofetil, and prednisolone for kidney transplantationIntramedullary enhancing spinal mass with sensory loss below T10 and marked motor weakness in both legs14 daysSurgical resection of the spinal mass and prednisolonePartial motor paralysisOur case78/FNonePulmonary GGO9 daysPrednisoloneImproved[^1]

In summary, we must recognize that in miliary tuberculosis being treated with ATT, a PR may present with a localized GGO in the lung. Patients without immunosuppression may be prone to developing a PR earlier than those who are immunosuppressed. In cases of PR with marked symptoms, steroid therapy may be valuable. More studies are necessary to decide the treatment course for a PR to ATT in miliary tuberculosis.
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